Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels

Journal of Gastroenterology

Volumn 43, Issue 6, 2008, Pages 484-491

  Fujiwara, Akiko ^a   Sakaguchi, Kohsaku ^a   Fujioka, Shinichi ^a   Iwasaki, Yoshiaki ^a   Senoh, Tomonori ^a   Nishimura, Mamoru ^a   Terao, Masako ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alanine aminotransferase; Chronic hepatitis B; Chronic hepatitis C; Fibrosis progression rate; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE;

EID: 47349132573     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2183-8     Document Type: Article

References (32)

1. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 1988;8:493-496.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956.
3. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-298.
4. Lok AS, McMahon BJ; Practice Guideline Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001;34:1225-12241.
5. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675.
6. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
7. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.
8. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group-inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;31:174-181.
9. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991;13:372-374.
10. Desmet VJ, Gerver M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-15120.
11. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;24:15-20.
12. Bedosa P, Poynard T, for the METAVIR Cooperative Study Group. An algorithm for grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293.
13. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58.
14. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-1047.
15. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
16. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
17. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
18. Mathurin P, Moussalli J, Cadranel J-F, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872.
19. Sobesky R, Mathurin P, Charlott F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. The MULTIVIRC Group. Gastroenterology 1999;116:378-386.
20. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-1058.
21. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
22. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-909.
23. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
24. Chu CM. Towards control of hepatitis B in the Asia-Pacific Region. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:E25-30.
25. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58.
26. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-181.
27. Sugauchi F, Mizokami M, Orito E, Ohno T, Koto H, Suzuki S, et al. A novel variant genotype C of hepatitis B virus identified in isolates from Australian aborigines: Complete genome sequence and phylogenetic relatedness. J Gen Virol 2001;82:883-892.
28. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the pre S2-region product. J Virol Methods 1999;80:97-112.
29. Papatheodoridis GV, Petraki K, Cholongitas E, Kanta E, Ketikoglon I, Manesis EK. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2005;12:199-206.
30. Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001;35:265-271.
31. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, Makino Y, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006;60:77-84.
32. Taniguchi H, Iwasaki Y, Fujiwara A, Sakaguchi K, Moriya A, Yu PC, et al. Long-term monitoring of platelet count, as a noninvasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol 2006;21:281-287.